Designed for busy lifestyles, these individually packed powder sticks are easy to carry and consume anytime, anywhere
How the study was designed Included adults 18 to 65 with type 2 diabetes who were newly prescribed one of three drug types: a GLP-1 receptor agonist (161,489 people), an SGLT-2 inhibitor (122,114 people), or a DPP-4 inhibitor (86,047 people)
adults diagnosed with obesity and roughly 35 million with Type 2 diabetes, its no wonder the popularity of GLP-1 therapies has skyrocketed, with numerous endorsements labeling them as miracle drugs. However, both doctors and patients are encountering challenges related to medication access, adherence, and insurance barriers
In plain terms, it jams a wasteful enzyme so cells hang onto two useful resources (SAM and NAD+ raw material) instead of burning them
S2CID 223462